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Context Glucagon-like peptide-1 (GLP-1) and the clinically available GLP-1 agonists have been 
shown to exert effects on the heart. It is unclear whether these effects occur at clinically used 
doses in vivo in humans, possibly contributing to CVD risk reduction. 
Objective To determine whether liraglutide at clinical dosing augments myocardial glucose 
uptake alone or in combination with insulin compared to insulin alone in metformin-treated Type 
2 diabetes mellitus. 
Design Comparison of myocardial fuel utilization after 3 months of treatment with insulin 
detemir, liraglutide, or combination detemir+liraglutide. 
Setting Academic hospital  
Participants Type 2 diabetes treated with metformin plus oral agents or basal insulin. 
Interventions Insulin detemir, liraglutide, or combination added to background metformin 
Main Outcome Measures Myocardial blood flow, fuel selection and rates of fuel utilization 
evaluated using positron emission tomography, powered to demonstrate large effects. 
Results We observed greater myocardial blood flow in the insulin-treated groups (median[25th, 
75th percentile]: detemir 0.64[0.50, 0.69], liraglutide 0.52[0.46, 0.58] and detemir+liraglutide 
0.75[0.55, 0.77] mL/g/min, p=0.035 comparing 3 groups and p=0.01 comparing detemir groups 
to liraglutide alone). There were no evident differences between groups in myocardial glucose 
uptake (detemir 0.040[0.013, 0.049], liraglutide 0.055[0.019, 0.105], detemir+liraglutide 
0.037[0.009, 0.046] µmol/g/min, p=0.68 comparing 3 groups).  Similarly there were no treatment 
group differences in measures of myocardial fatty acid uptake or handling, and no differences in 
total oxidation rate. 
Conclusions These observations argue against large effects of GLP-1 agonists on myocardial 
fuel metabolism as mediators of beneficial treatment effects on myocardial function and 
ischemia protection. 
PET studies showed no effect of liraglutide to alter myocardial fuel selection in metformin-treated T2D. 
This argues against a myocardial metabolic effect in the CVD benefits of GLP-1 treatments. 
Background 
Glucagon-like peptide 1 (GLP-1) based treatments have been developed for the management of 
Type 2 diabetes mellitus (T2D). Shortly after the discovery of GLP-1 and its effects via the 
pancreas to regulate glucose metabolism, GLP-1 was found to have extrapancreatic effects 
including effects to modulate myocardial metabolism and function (1). Specifically, GLP-1 
exposure can acutely augment myocardial glucose uptake, and this effect has been postulated to 
contribute to cardiac protection under ischemia and to improvements in cardiac function (2). We 
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and others have shown that these effects can be replicated in small and large animal models, and 
in lean non-diabetic humans (3-7). Importantly, however, we have demonstrated an impairment 
in myocardial metabolic effects of GLP-1 agonism in humans with T2D and in obese non-
diabetic swine (3). This is potentially important, as the clinical populations treated with GLP-1 
agonists have obesity and/or T2D. 
This impairment in GLP-1 metabolic responses in the heart is parallel to reports of impaired 
myocardial responses to insulin in obesity and in T2D (8). The genesis of myocardial insulin 
resistance is not fully explained, but it has been attributed in part to impairment of myocardial 
insulin signaling  leading to impaired insulin-stimulated glucose uptake (9) and in part to 
augmented fatty acid uptake by the heart (10) leading to impaired myocardial metabolic 
flexibility. GLP-1 appears to exert effects directly on the heart to drive myocardial glucose 
uptake, via pathways that are independent of myocardial insulin signaling (3,11). This suggests 
the possibility that GLP-1 and insulin actions on myocardial glucose uptake could converge, and 
perhaps GLP-1 could help overcome myocardial insulin resistance (12).  
The actions of current GLP-1 agonists on the myocardium in people with Type 2 diabetes 
have not been fully described. It is unknown whether the doses that have been developed and 
approved for the management of glycemia exert metabolic actions on the heart, and how those 
actions relate to the effects of insulin on heart metabolism. We hypothesized that GLP-1 mimetic 
in combination with insulin would provide superior stimulation of myocardial glucose uptake 
compared to either agent alone. Therefore we undertook a randomized clinical trial using 
positron emission tomography, powered to demonstrate large effects, to compare the effects of 
insulin detemir, liraglutide, or the combination, on myocardial fuel metabolism in people with 
Type 2 diabetes. 
Methods 
Population 
Volunteers were recruited by advertising. Inclusion criteria included T2D of at least 2 years’ 
duration stably treated with metformin >= 1500 mg/day, age 18-50 years, HbA1c 7.0 – 10.0%, 
and treatment with up to 2 oral antidiabetic agents and/or basal insulin. Key exclusion criteria 
included exposure within the past 6 months to a DPP4 inhibitor, GLP-1 agonist, or 
thiazolidinedione class diabetes agent; known coronary artery disease or structural heart disease; 
known diabetic microvascular disease (urinary albumin/creatinine ratio>30 mg/g, diagnosed 
retinopathy or neuropathy by self-report, or either of these detected on screening physical 
examination); and contraindications to radiation exposure with planned positron emission 
tomography. The flow of participants through the study is presented in Figure 1. All participants 
gave written informed consent for their participation in the study, and the study was conducted 
according to the Helsinki principles. This study was registered on ClinicalTrials.gov 
(NCT01232946) 
Treatment 
Volunteers were randomized in a fixed-block design to one of three treatments: insulin, 
liraglutide, or combination insulin and liraglutide. Antidiabetes agents other than metformin 
were discontinued, and study treatment was substituted in addition to ongoing metformin; if 
participants were taking submaximal metformin dosing an attempt was made to increase this to 
2000 mg/day prior to randomization. The long-acting insulin detemir was used, with dosing 
initiated at 5-10 units twice daily (depending on the current blood glucose readings) and titrated 
twice weekly to achieve fasting glucose values below 120 mg/dL (6.7 mmol/L) without values 
AD
VA
N
CE
 A
RT
IC
LE
:
TH
E 
JO
UR
NA
L 
O
F 
CL
IN
IC
AL
 
EN
D
O
CR
IN
O
LO
G
Y 
& 
M
ET
AB
O
LI
SM
JC
EM
Downloaded from https://academic.oup.com/jcem/advance-article-abstract/doi/10.1210/jc.2018-00712/5055106
by IUPUI University Library user
on 18 July 2018
AD
VA
NC
E 
AR
TI
CL
E
The Journal of Clinical Endocrinology & Metabolism; Copyright 2018  DOI: 10.1210/jc.2018-00712 
 
 
3
below 80 mg/dL (4.4 mmol/L). Liraglutide dosing followed the product labeling, starting with 
0.6 mg/day initially and increased weekly to 1.8 mg/day. Participants randomized to combination 
therapy started first on liraglutide and had insulin added when stable liraglutide dosing was 
achieved. PET measurements of myocardial metabolism were planned at the end of 12 weeks of 
study assigned treatment.   
Study Measurements 
Subjects were admitted to the Indiana University Clinical Translational Sciences Institute's 
Clinical Research Center before 0700h the morning of the PET study, following an overnight 
fast (from 2000h the day prior). Anthropometrics, blood pressure and heart rate were measured 
in a standardized manner. Body composition was measured using dual-energy X-ray 
absorptiometry. An intravenous catheter was placed in the antecubital vein of one arm for 
infusates. A second catheter was placed in the contralateral arm for blood sampling.  
Liraglutide treated subjects received a subcutaneous injection of liraglutide 1.8 mg at 0800h 
on the morning of the PET study. Insulin treated subjects took their stable morning insulin 
detemir dose also at 0800h the morning of the study. The PET measurement protocol began 
between 1000-1100h.  
PET protocol 
Positron emission tomography (PET) was used to measure cardiac perfusion and oxidative 
metabolism (11C-acetate), fatty acid uptake and oxidation (11C-palmitate) and glucose uptake 
(18F-deoxyglucose) under resting fasting conditions with hormone exposure. Blood samples for 
later measurement of circulating concentrations of glucose, insulin, and non-esterified fatty acids 
were taken at the beginning and end of the PET measurement sequence, with average values 
calculated to reflect exposure during the PET measurements.  
Conventional data acquisition procedures were used to acquire and reconstruct the PET 
images. This included a transmission measurement to enable correction for attenuation by body 
mass. The image data were reconstructed using conventional filtered back-projection algorithms 
and a Hanning smoothing filter, which produces an image resolution of 1.0 cm full-width at half-
maximum. This filter function was selected because it is consistent with the observed resolution 
degradation observed by the motion of the heart as determined with cardiac gated imaging 
studies. Custom software was used to identify the entire left ventricle as a single volume of 
interest and then apply mathematical modeling to the resulting volume of interest. The left 
ventricle cavity, concurrently identified, served as an arterial blood pool from which the input 
function was derived. Following acetate infusion, serial timed peripheral blood samples were 
taken (at minutes 0, 3, 6, 10, 15, 20, 25, and 30), immediately analyzed for circulating 
concentrations of labeled CO2 and later used as a correction for the input function (13,14). Timed 
samples were taken at these same intervals following palmitate infusion and assayed for total and 
palmitate-specific radioactivity to determine metabolite corrections for this analyte’s input 
function. Tissue perfusion and total oxidative metabolism were quantified from the myocardial 
time-activity curve following 11C-Acetate injection, using a well-validated two-compartment 
model (13,15). Myocardial blood flow was measured directly from the acetate influx kinetic 
parameter K1 (15,16). Myocardial oxygen consumption was derived from the acetate efflux 
parameter k2 using MVO2 = 135*k2 -0.96 (17). A 3-compartment, 3-free parameter model 
including uptake, oxidation and esterification kinetics was used to derive rates of fatty acid 
utilization from the palmitate time-activity curves (18), with net rates of fatty acid oxidation and 
esterification calculated according to the method of Bergmann (19). Myocardial glucose uptake 
was quantified from the time-activity curve following 18FDG injection using a 3-compartment 
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model, according to the methods of Morita and colleagues (20), with a lumped constant of 1.0 
(21,22). 
Sample Size Estimation and Statistical Approach  
Myocardial glucose uptake was our primary endpoint for analysis; other PET-derived measures 
were co-secondary endpoints. We were specifically interested in whether the combined exposure 
produced myocardial metabolic rates greater than exposure to insulin alone. Our pre-specified 
plan for statistical testing was constructed to first evaluate whether the three treatment groups 
were different with post-hoc pairwise testing if indicated, and then to compare 2 liraglutide 
groups against insulin alone, and 2 insulin groups against liraglutide alone. Post-hoc analyses 
including multivariable analyses with relevant covariates were planned as exploratory analyses; 
due to unexpected group differences in some baseline factors, post-hoc sensitivity analyses were 
performed evaluating direct and interaction effects of these factors on the main three-group 
outcome. A significance p value of <0.05 was applied throughout without adjustment for 
multiple testing. 
Power estimates and sample size calculations were based on the primary endpoint of 
myocardial glucose uptake. Our prior work suggested that the myocardial glucose uptake in T2D 
would be ~0.026±0.016 µmol/g/min (mean±SD), and studies by others suggested that diabetes 
therapies added to background treatments could induce 30-40% increases in myocardial glucose 
uptake, i.e. effect sizes of ~0.7 SD (23,24). We estimated that a sample size of 9 per group would 
permit demonstrating between-group differences of ~1.2 SD with alpha=0.05 and beta=0.2 for 
myocardial glucose uptake. Therefore we were powered to demonstrate moderate to large 
effects, if present. Working from this glucose uptake-related sample size we estimated 
demonstrable between-group differences of ~0.5 SD for myocardial blood flow, ~1.4 SD for 
total myocardial oxidation rates, and ~0.6 SD for myocardial fatty acid oxidation rates.  
The PET data for metabolite rates were right-skewed, and not adequately normalized by 
standard transformations (logarithmic, square root, inverse). Therefore we applied non-
parametric testing, using Kruskal-Wallis tests to compare across 3 treatment groups and Mann-
Whitney U tests for pairwise testing. These skewed distributions were best represented in the 
figures by plotting median and 75th percentile values. Sensitivity analyses evaluating the 
potential effects of baseline group differences were performed using standard ANOVA with 
untransformed data excluding extreme outliers, in order to meet the assumptions of the method.  
Results 
The flow of participants through the study is presented in Figure 1, and the characteristics of the 
participants who enrolled and completed the study are presented in Table 1. Two participants 
originally randomized to receive combination insulin detemir plus liraglutide withdrew; one 
experienced intolerable adverse gastrointestinal effects and another was lost to follow-up without 
any known reason for withdrawal. One participant originally randomized to the detemir arm died 
of a narcotic overdose after randomization.  
The most notable feature of the baseline characteristics was the unbalanced sex distribution 
across treatment groups. Despite block randomization, the detemir-only group had proportionally 
more female participants and fewer male participants than the other two groups (p=0.007). There 
was also a modest imbalance in race distribution, with proportionally more black participants in 
the combination treatment group, not achieving significance (p=0.090). Borderline differences 
were also seen with respect to glucose and HbA1c (lower in the detemir-only group, p=0.084 and 
0.060 respectively); body fat measurements were available in 7 detemir participants 
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(40.6±6.7%), in 5 liraglutide participants (32.6±10.8%) and in 6 combination treatment 
participants (41.4±3.8%), p=0.08 comparing groups. The groups were well balanced with regard 
to age, weight, BMI and blood lipid levels (all p>0.40). 
The median metformin dose was 2000 mg/d, with only 3 participants taking less; all 
participants were taking at least 1500 mg/d. All participants who were randomized to receive 
liraglutide and completed the study achieved stable dosing at 1.8 mg/d. The insulin detemir dose 
was individualized, guided by fasting blood glucose levels as above. The median daily dose was 
15 units, with a range from 5 to 68 units per day. 
All three treatment groups experienced significant improvements in glycemia over the course 
of 3 months’ treatment (p=0.04; Table 2), without a statistical difference between groups 
(p=0.12). Weight fell across all 3 treatment groups (p=0.007); one individual in the liraglutide 
group lost 15.7 Kg, but otherwise the weight loss was 1.7±2.4 Kg (mean±SD) and did not differ 
between treatment groups. Heart rate was unchanged across the course of treatment, and not 
different between groups at the end of treatment (Table 2). Systolic blood pressure fell 
significantly (p=0.013), not different between groups (p=0.28). Diastolic blood pressure also fell 
significantly (p=0.006) and this effect differed between groups (p=0.029) owing to larger 
changes in the detemir-only group.  
On the day of the PET studies, the three groups did not differ in hemodynamic parameters 
(Table 2). Importantly, serum glucose values across the interval of PET scanning did not differ 
between groups (Figure 2). Non-esterified fatty acid concentrations were numerically but not 
statistically lower in the detemir+liraglutide group compared to others (Figure 2). Insulin 
concentrations were statistically higher in the participants randomized to detemir alone or to 
detemir+liraglutide (Figure 2), reflecting the steady state from prior treatment plus the AM dose 
on the morning of the study. 
There were no observed differences between groups in the PET-derived measure of oxygen 
consumption (MVO2; Figure 3). We did observe differences between groups in myocardial 
perfusion (myocardial blood flow, MBF), with greater rates of blood flow in the two detemir-
treated groups compared to the liraglutide-only group. These group differences in blood flow 
were directionally consistent with the MVO2 group differences, but the correlation between MBF 
and MVO2 was not statistically significant (r=0.25, p=0.22; not shown). The rate-pressure 
product (mean arterial pressure x heart rate) divided by MVO2 was calculated as an index of 
work efficiency (16,25) and was statistically greater in the liraglutide-only group compared to 
the two groups that received insulin (Figure 3). 
We did not observe any differences between groups in the measures of myocardial glucose 
uptake, fatty acid oxidation or fatty acid esterification (Figure 4). The primary hypothesis for this 
study was that the combination detemir plus liraglutide group would exhibit a higher myocardial 
glucose uptake than detemir alone; this was unequivocally not seen, with these  two groups 
showing essentially identical median measures of MGU (detemir 0.040 µmol*g-1*min-1, 
detemir+liraglutide 0.037, p=0.65; Figure 4). The liraglutide-only group had a numerically but 
not statistically higher median MGU (0.055 µmol*g-1*min-1, p=0.57 against detemir alone). 
Similarly, the three treatment groups did not differ in the median values of the palmitate-derived 
measures of fatty acid utilization (MFAO median detemir 0.123 µmol*g-1*min-1, liraglutide 
0.102, detemir+liraglutide 0.099, p=0.60; Figure 4). The measured kinetic rates, distinct from 
substrate availability, were also not different across treatment groups (e.g. glucose kinetic 
median detemir 5.5x10-3 min-1, liraglutide 8.25x10-3, combination 4.65x10-3, p=0.69; fatty acid 
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oxidation kinetic detemir 165.6x10-3 min-1, liraglutide 116.4x10-3, combination 139.5x10-3, 
p=0.80).   
The observed effects on glucose uptake included high outlier values in one detemir-only 
treated participant and one liraglutide-only treated participant.  The use of non-parametric 
statistical testing protects against effects of outliers, but we also performed sensitivity testing 
excluding these 2 individuals. Doing so did not alter the outcome (p=0.84 for MGU comparing 3 
groups). The measures of blood flow, total oxidation and fatty acid handling from these 
individuals were not outliers, and parallel sensitivity analyses did not alter any of the 
comparisons between these other PET-derived parameters. 
Sex, race, baseline glucose and baseline HbA1c were at least nominally different across 
treatment groups at baseline (Table 1). However none of these factors was significantly 
associated with the PET measures of fuel uptake, with the strongest correlation among these 
relating HbA1c with MFAE (Spearman’s rho -0.35, p=0.09) and most r values below 0.10. 
Sensitivity analyses were performed to further evaluate possible contributions of these 
imbalances. The results for sex, race, and baseline HbA1c are presented in Supplemental Table 
1. Overall these analyses showed no direct or interaction effect of these variables on the PET-
derived outcomes; however there were two interesting exceptions. First, myocardial glucose 
uptake was significantly different by treatment groups after adjustment for sex, higher in the 
liraglutide treatment arm than the other two groups (p<0.001) and with higher MGU in male 
participants. Second, myocardial fatty acid oxidation was significantly different across treatment 
groups after adjustment for baseline HbA1c, lower in the levemir treatment arm than the other 
two groups (p=0.021) with higher baseline HbA1c relating to higher on-treatment MFAO. This 
was seen despite equalization of glucose control across the treatment interval prior to PET 
measures. These observations do not affect the overall conclusion that combination therapy did 
not augment fuel use compared to detemir or liraglutide alone. 
In summary, treatment with combination detemir plus liraglutide did not produce different 
rates of fuel use or different patterns of fuel selection compared to insulin alone or liraglutide 
alone.  
Discussion 
We measured myocardial fuel utilization after 12 weeks of randomized therapy with the long-
acting insulin detemir, the long-acting GLP-1 mimetic liraglutide, or the combination of these 
treatments in humans with Type 2 diabetes (T2D) treated with maximal dose metformin. In vivo 
measurements of myocardial fuel uptake were made using positron emission tomography (PET). 
Study medications were administered the morning of the PET measurements. We observed 
expected effects of insulin treatment to increase myocardial blood flow in both groups that 
received insulin, but otherwise we observed no differences between groups in the rates of fuel 
metabolism or fuel selection. These data include two distinct novel observations in type 2 
diabetes without cardiovascular disease: First, liraglutide alone at clinically used doses does not 
stimulate myocardial glucose uptake compared to insulin; Second, liraglutide at clinically used 
doses was not able to augment insulin’s effects to drive myocardial glucose uptake.  
Our primary endpoint was PET-measured myocardial glucose uptake, and our sample size 
provided a priori power to detect ~1.2xSD differences in this parameter. We were able to 
demonstrate expected between-group differences in the effect of insulin on myocardial blood 
flow, demonstrating the viability of the overall approach for showing detectable differences. 
Nevertheless, the results did not suggest any material difference in myocardial glucose uptake 
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between groups, with nearly identical group median values and a very high p value comparing 
the distribution of values. Therefore, although our threshold for demonstrating a change was 
high, the observed group difference does not suggest that the absence of group differences is a 
power issue. Similarly, the observed effects on all aspects of fatty acid handling were 
convincingly equal across groups. These observations clearly disprove the hypothesis that 
liraglutide alone or in combination with insulin would provide superior stimulation of 
myocardial glucose uptake compared to insulin alone.  
Soon after the discovery of GLP-1, this gut peptide was found to exert hemodynamic and 
metabolic effects in the heart, including protection from the effects of ischemia in mouse models 
(1,26-28). Subsequently a growing body of animal studies show cardiac benefits of GLP-1 
agonists via a variety of mechanisms including activation of p38alpha MAP-kinase (11), and 
improving intracellular calcium homeostasis (29), among others. A major hypothesized 
mechanism of benefit has been a favorable shift in myocardial metabolite selection induced by 
GLP-1 agonism (2).  
It is interesting to note that the MGU rates were not different across the three treatment 
groups in our study, despite higher insulin concentrations in the insulin-treated participants 
compared to those receiving liraglutide alone. This implies that exposure to therapeutic levels of 
liraglutide provides similar stimulation of myocardial glucose uptake as seen with exposure to 
therapeutically achieved insulinemia. This could reflect similar direct effects, or similar degrees 
of resistance to the effects. In this regard we note that the observed levels of MGU were 
objectively low (consistent with low rates described in prior PET studies in obesity or Type 2 
diabetes under fasting conditions (3,30,31), which suggests that these observations reflect 
parallel resistance to the glucose-uptake stimulating effects of insulin and liraglutide in type 2 
diabetes.  
In large-scale clinical trials, beneficial cardiovascular effects including reduced rates of 
myocardial infarction and death have been seen with some GLP-1 agonists (liraglutide, 
semaglutide) (32,33) but not others (lixisenatide, long-acting exenatide) (34,35). The 
mechanisms underlying these beneficial effects, or the lack thereof, are unknown. As noted 
above the antecedent preclinical work suggested that changes in fuel selection might contribute 
to these effects.  However, there are very few studies of effects of GLP-1 agonists on myocardial 
fuel metabolism in humans. In people with congestive heart failure liraglutide improved systemic 
glucose metabolism but failed to improve myocardial glucose uptake or myocardial blood flow 
or flow reserve (36). Similarly, albiglutide treatment in people with NYHA II or III class heart 
failure improved some measures of cardiac function but did not improve myocardial glucose 
consumption or oxygen consumption (37). Exenatide improved myocardial blood flow without 
changing myocardial glucose uptake (6), although in that dataset a direct relationship was 
observed between the change in myocardial glucose uptake and baseline insulin resistance. The 
current observations are the first in a study cohort that is typical of the general population of 
Type 2 diabetes patients treated with liraglutide. 
We indirectly addressed whether GLP-1 added to insulin could overcome myocardial insulin 
resistance. There are some data to suggest this is possible. In lean dogs, GLP-1 co-treatment was 
sufficient to restore insulin-mediated myocardial glucose uptake in the setting of chronic heart 
failure (12). In an observational clinical study, adding liraglutide to ongoing diabetes treatments 
in Type 2 diabetes for 6 months was associated with improved echocardiographic markers of 
diastolic function (38). In patients with Type 2 diabetes and known coronary artery disease 
studied in a prospectively randomized design, echocardiographically-measured cardiac function 
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was unaffected by insulin infusion alone but improved with co-infusion of GLP-1 (significantly 
improved strain and systolic tissue velocity, but unchanged ejection fraction) (39). One study has 
reported reductions in major atherosclerotic cardiovascular events with adding liraglutide to 
insulin (40). Collectively these observations suggest that combination therapy does not detract 
from hemodynamic or metabolic benefits of individual components, although our current 
observations suggest that effects on myocardial fuel selection do not explain the observed 
benefits. 
Strengths of this work include the use of typical clinical dosing in the usual target population, 
randomized assignment to treatment, and the use of high-quality, high-sensitivity measurements 
of myocardial fuel utilization with PET. The choice to include metformin as a background 
treatment condition improves the ability to translate this work to the general circumstance of 
clinical application of liraglutide, but also raises the possibility that our negative results could be 
due to an unexpected effect of metformin to dominate the apparent treatment response; this 
seems unlikely given the low absolute rates of MGU overall. Limitations of this work include the 
relatively low total insulin exposure, which was determined by each individual’s clinical need 
based on achieved fasting blood glucose levels. We were powered only for demonstrating large 
between-group differences in our main outcome measure, MGU, but the approximately equal 
median and distribution across groups argues against a power problem in this finding. It would 
have been ideal to perform paired measurements of myocardial fuel selection before and after 
therapy but this was not possible within the available resources. We performed studies under 
resting conditions; it is possible that differential responses could be seen under circumstances of 
physiologic or pathophysiologic demand (i.e. exercise or ischemia). We were not powered a 
priori for post-hoc analyses, so the results of these evaluations need to be considered exploratory. 
The sex imbalance across treatment groups at baseline might have resulted in imbalanced 
measures of myocardial fatty acid handling, as women and men differ in this aspect of cardiac 
fuel selection (41,42); the sensitivity analysis suggests the possibility of a difference in response 
across treatments but does not alter the overall conclusion that combination therapy failed to 
augment myocardial glucose uptake or other measures of fuel selection compared to individual 
treatments.  
Conclusions 
These observations suggest that liraglutide alone in clinically used dosing in patients with Type 2 
diabetes does not induce alterations in resting, fasting myocardial fuel uptake or fuel selection, 
and that liraglutide was not able to augment the effects of insulin alone on myocardial fuel 
uptake or selection under these conditions. These observations argue against large effects of 
GLP-1 agonists on myocardial fuel metabolism as mediators of beneficial treatment effects on 
myocardial function and ischemia protection. 
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Figure 1. Flow of study participants. One participant in the detemir-only arm died of non-study 
related causes during randomized treatment. 
Figure 2 – Achieved insulin, glucose and fatty acid concentrations at the time of the PET 
measurements. Bars present median values and whiskers present upper 75th percentile values. 
Insulin concentrations were significantly different across the 3 groups, with significance in the 
pairwise comparison of detemir groups versus liraglutide alone. The other measures were not 
significantly different between groups. 
Figure 3 – Myocardial blood flow, oxygen consumption, and work efficiency. Bars present 
median values and whiskers present upper 75th percentile values. Liraglutide alone showed lower 
blood flow and greater work efficiency than the other two groups. MBF, myocardial blood flow; 
MVO2, myocardial oxygen consumption; RPP, rate-pressure product. 
Figure 4 – Myocardial fuel consumption. Bars present median values and whiskers present 
upper 75th percentile values. There were no significant differences across groups in these 
measures. MGU, myocardial glucose uptake; MFAO, myocardial fatty acid oxidation; MFAE, 
myocardial fatty acid esterification.  
Table 1 – Participant Characteristics 
Variable Detemir Liraglutide Detemir+Liraglutide P value (ANOVA) 
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Race (B/W) 3/6 3/6 7/2 0.090 
Sex (F/M) 7/2 2/7 8/1 0.007 
Age (yrs) 52.1±8.6 53.9±5.3 49.2±9.0 0.45 
Weight (kg) 94.8±20.0 99.3±17.9 88.7±19.6 0.50 
Height (m) 1.64±0.09 1.74±0.06 1.61±0.04 0.002 
BMI (kg/m2) 35.1±7.2 33.4±±6.8 34.2±6.9 0.87 
Total Cholesterol (mmol/L) 3.4±1.4 3.8±1.4 3.8±0.8 0.77 
LDL Cholesterol (mmol/L) 1.8±1.4 2.2±1.2 2.2±0.9 0.76 
HDL Cholesterol (mmol/L) 0.9±0.3 0.8±0.2 1.0±0.2 0.42 
Triglycerides (mmol/L) 1.9±1.1 2.0±1.0 1.5±0.9 0.60 
Glucose-Screening (mmol/l) 6.5±2.6 9.4±3.2 9.3±3.1 0.084 
HbA1c - Randomization (%) 7.00±0.79 7.59±0.96 8.13±0.99 0.060 
HbA1c – Randomization (mmol/mol) 53±6 60±8 64±9 0.060 
Table 1 Note: Values presented as mean±SD. The P value represents testing for a difference among the 3 groups by 
analysis of variance. B, black; BMI, body mass index; F, female; M; male; W, white. 
Table 2 – Treatment Effects 
Variable Randomization Month 1 Month 2 Study Day P value 
(Time) 
P value 
(Treatment*Time) 
Fasting Glucose (mmol/L)     0.04 0.12 
Detemir 6.5±2.6 7.2±0.9 6.9±1.4 7.8±2.9   
Liraglutide 9.4±3.2 6.9±1.1 7.2±1.8 7.3±2.4   
Detemir+Liraglutide 9.3±3.1 7.2±1.9 6.2±0.8 6.9±1.4   
Weight (Kg)     0.007 0.69 
Detemir 97.4±19.7 97.3±20.9 96.8±7.0 95.7±7.0   
Liraglutide 103.1±7.8 101.8±7.7 100.8±7.5 100.1±7.5   
Detemir+Liraglutide 88.3±8.5 86.9±8.3 86.9±8.1 87.1±8.1   
Heart Rate (bpm)     0.93 0.82 
Detemir 69.9±3.3 72.7±3.0 70.9±3.3 69.9±4.0   
Liraglutide 72.3±4.4 70.3±3.9 71.3±4.4 74.0±5.3   
Detemir+Liraglutide 71.3±3.6 70.8±3.2 75.8±3.6 70.8±4.3   
Systolic BP (mmHg)     0.013 0.28 
Detemir 149.2±6.8 129.8±4.4 127.8±5.3 122.2±7.1   
Liraglutide 136.0±8.3 135.3±5.3 136.0±6.5 119.5±8.7   
Detemir+Liraglutide 131.2±7.4 126.8±4.8 121.8±5.8 126.0±7.8   
Diastolic BP (mmHg)     0.006 0.029 
Detemir 78.4±2.3 71.0±2.0 70.9±2.1 66.1±2.8   
Liraglutide 76.0±2.3 70.4±2.0 76.1±2.1 72.9±5.8   
Detemir+Liraglutide 73.0±2.5 74.0±2.2 73.3±2.3 72.3±3.0   
Table 2 Note: P values are presented evaluating changes over time for all groups combined (Time), and testing 
whether this difference over time differed among treatment groups (Treatment*Time interaction). BP, blood 
pressure. 
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